PFE - Pfizer-Genmab cervical cancer drug gets accepted for EU review
2024-02-02 07:13:49 ET
More on Genmab, Pfizer, etc.
- Pfizer Is Down 54% From Highs, Now Yields 6.1%
- Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disagree With The Market
- Pfizer Inc. (PFE) Q4 2023 Earnings Call Transcript
- U.S. govt. opens bids in Medicare drug price negotiations
- 5 stocks to watch on Tuesday: Pfizer, AMD, Microsoft and more